Jasper Therapeutics(JSPR)
$11.77-1.91 (-13.96%)
JSPR
Jasper Therapeutics stock drug pipeline
$11.77
At close:-1.91 (-13.96%)
Want to see JSPR full AI Analyst Report?
Jasper Therapeutics (JSPR) Drug Pipeline
1,073 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Briquilimab | Urticaria Chronic | Phase II | Enrolling By Invitation | A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials | Nov 20, 2024 | ― |
| Briquilimab | Allergic Asthma | Phase I | Terminated | A Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic Asthma | Sep 06, 2024 | ― |
| Briquilimab | Chronic Inducible Urticaria | phase1AndPhase2 | Terminated | A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines | Apr 03, 2024 | ― |
| Briquilimab | Chronic Spontaneous Urticaria | phase1AndPhase2 | Recruiting | Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients with Chronic Spontaneous Urticaria (CSU) | Nov 21, 2023 | ― |
| Jsp191 | Lower-Risk Myelodysplastic Syndrome | Phase I | Terminated | JSP191 (briquilimab) in Subjects with LR-MDS | Jun 05, 2023 | ― |
| Humanized Anti-Cd117 Monoclonal Antibody (Jsp191) | Scid | phase1AndPhase2 | Terminated | JSP191 Antibody Targeting Conditioning in SCID Patients | Nov 02, 2016 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Briquilimab | Phase II | Urticaria Chronic | Enrolling By Invitation | A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials | Nov 20, 2024 | ― |
| Briquilimab | Phase I | Allergic Asthma | Terminated | A Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic Asthma | Sep 06, 2024 | ― |
| Briquilimab | phase1AndPhase2 | Chronic Inducible Urticaria | Terminated | A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines | Apr 03, 2024 | ― |
| Briquilimab | phase1AndPhase2 | Chronic Spontaneous Urticaria | Recruiting | Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients with Chronic Spontaneous Urticaria (CSU) | Nov 21, 2023 | ― |
| Jsp191 | Phase I | Lower-Risk Myelodysplastic Syndrome | Terminated | JSP191 (briquilimab) in Subjects with LR-MDS | Jun 05, 2023 | ― |
| Humanized Anti-Cd117 Monoclonal Antibody (Jsp191) | phase1AndPhase2 | Scid | Terminated | JSP191 Antibody Targeting Conditioning in SCID Patients | Nov 02, 2016 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Jasper Therapeutics, Inc. (JSPR) have in its pipeline
Jasper Therapeutics JSPR is currently developing the following drugs: Briquilimab, Jsp191, Humanized Anti-Cd117 Monoclonal Antibody (Jsp191). These drug candidates are in various stages of clinical development as the company works toward FDA approval.

